Contact
Please use this form to send email to PR contact of this press release:
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
TO:
Please use this form to send email to PR contact of this press release:
Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
TO: